Similarly, the MIRRA and MANDARA trials (6, 7) evaluated IL-5/IL-5R antagonists as add-on agents in patients with relapsing or corticosteroid-dependent EGPA, rather than exploring their effect as induction therapy. This evidence concerns the gene IL5 and eosinophilic granulomatosis with polyangiitis.